NCT01511510

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

A Phase I, Randomized, Subject And Investigator Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of ascending doses administered once daily for 14 days in healthy volunteers.

Detailed description

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	PF-04958242	PF-04958242 0.05 mg oral solution Q24 hours for 14 days
DRUG	PF-04958242	PF-04958242 0.10 mg oral solution Q24 hours for 14 days
DRUG	PF-04958242	PF-04958242 0.15 mg oral solution Q24 hours for 14 days
DRUG	PF-04958242	PF-04958242 0.25 mg oral solution Q24 hours for 14 days
DRUG	Placebo	Placebo oral solution Q24 hours for 14 days

Timeline

• Start date: 2011-06-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2012-01-18
• Last updated: 2019-11-21

Locations

1 site across 1 country: United States